BRIEF published on 07/28/2025 at 07:35, 9 months 4 days ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
PRESS RELEASE published on 07/28/2025 at 07:30, 9 months 4 days ago Inside Information / Other news releases Advicenne obtains marketing authorization and reimbursement for Sibnayal® in Saudi Arabia, a fixed combination for rare kidney diseases, in collaboration with Taïba Healthcare Saudi Arabia Advicenne Reimbursement Marketing Authorization Sibnayal
BRIEF published on 07/25/2025 at 07:35, 9 months 7 days ago Advicenne Announces 9% Revenue Growth for H1 2025 Growth Turnover Advicenna Sibnayal® Pharmaceutical Markets
PRESS RELEASE published on 07/25/2025 at 07:30, 9 months 7 days ago Inside Information / Other news releases Advicenne reports H1 2025 sales of €2.6 million, with direct sales rising 17% and Sibnayal® sales in Europe up 90% compared to H1 2024. Company's cash flow horizon extends to Q3 2026 Cash Flow Pharmaceutical Advicenne Sibnayal H1 2025 Sales
BRIEF published on 07/21/2025 at 20:57, 9 months 11 days ago Advicenne raises 2.6 million euros to strengthen its financial capacity Capital Increase Financial Market Bpifrance Kidney Diseases Advicenna
BRIEF published on 03/27/2025 at 19:17, 1 year 1 month ago Advicenne Reports Solid Growth and Future Plans for 2025 Cash Flow Improvement 2025 Outlook Advicenne Financial Results Sibnayal Sales Growth ADV7103 Regulatory Progress
PRESS RELEASE published on 03/27/2025 at 19:12, 1 year 1 month ago Inside Information / News release on accounts, results Advicenne reports successful commercial performance of Sibnayal® in Europe, with total product sales up 9.4% to €4.9m. Major strides in US development with NDA filing expected in Q3 2025 Financial Results Advicenne Commercial Performance Sibnayal US Development
BRIEF published on 10/01/2024 at 07:05, 1 year 7 months ago Advicenne Advances in US with Positive FDA Reviews for ADV7103 FDA ADV7103 ATRd Advicenna Cystinuria
PRESS RELEASE published on 10/01/2024 at 07:00, 1 year 7 months ago Inside Information / Other news releases Advicenne achieves major milestones in the US with positive FDA opinions on ADV7103, accelerating partnership outlook for commercialization, preparing for clinical development in cystinuria, and seeking commercial partners Commercialization Advicenne ADV7103 Cystinuria FDA Opinions
BRIEF published on 05/15/2024 at 09:07, 1 year 11 months ago Advicenne Shareholders Approve Board-Supported Resolutions at General Meeting Euronext Growth Paris Pharmaceutical Industry General Meeting Advicenne Rare Renal Diseases
Published on 05/01/2026 at 22:30, 21 minutes ago Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing
Published on 05/01/2026 at 22:30, 21 minutes ago Apex Critical Metals Announces Extension of Marketing Agreement with Rumble Strip Media Inc.
Published on 05/01/2026 at 18:00, 4 hours 51 minutes ago Star Copper to Present at the Emerging Growth Conference on May 7, 2026
Published on 05/01/2026 at 15:35, 7 hours 16 minutes ago LNG Energy Group Announces Partial Revocation of Cease Trade Order and Proposed Private Placement
Published on 05/01/2026 at 19:23, 3 hours 28 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 17:45, 5 hours 6 minutes ago Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 5 hours 30 minutes ago Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 04/30/2026 at 20:00, 1 day 2 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 3 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 3 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 4 hours ago Minutes of the Combined General Meeting held on April 30, 2026
